|
Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Within I.V. generic drugs, Fresenius Kabi counts among the leading suppliers in the U.S. market.
We are focused on the therapy and care of critically and chronically ill patients in and outside the hospital.
Fresenius Kabi has more than 21,000 employees worldwide and a global network of around 55 sales organizations and more than 55 production sites. In 2009, Fresenius Kabi sales were € 3,086 million and the companys EBIT was € 607 million.
Fresenius Kabi AG is a 100% subsidiary of the health care group Fresenius SE.
Key Figures
| €m | 2009 | 2008 | Change |
 | | | |
| Sales | 3,086 | 2,495 | 24 % |
| EBITDA | 742 | 544 | 36 % |
| EBIT | 607 | 443 | 37 % |
| Net Income* | 200 | 200 | 0 % |
| Employees | 21,872 | 20,457 | 7 % |
| | | |
*Net income attributable to Fresenius Kabi AG. | 
